ChiCTR2600121063 版本V1.0 版本创建时间2026/03/25 08:52:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121063 

最近更新日期:

Date of Last Refreshed on:

2026-03-25 08:52:45 

注册时间:

Date of Registration:

2026-03-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经耳迷走神经刺激在扁桃体术后镇痛中的应用:一项随机对照试验

Public title:

Transcutaneous auricular vagus nerve stimulation for postoperative analgesia after adult tonsillectomy: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经耳迷走神经刺激在扁桃体术后镇痛中的应用:一项随机对照试验

Scientific title:

Transcutaneous auricular vagus nerve stimulation for postoperative analgesia after adult tonsillectomy: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈儒 

研究负责人:

陈儒 

Applicant:

Ru Chen 

Study leader:

Ru Chen 

申请注册联系人电话:

Applicant telephone:

+86 82519999

研究负责人电话:

Study leader's
telephone:

+86 82519999

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

allergychen@163.com

研究负责人电子邮件:

Study leader's E-mail:

allergychen@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

First Hospital of Jiaxing

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国浙江省嘉兴南湖区中环南路1882号

研究负责人通讯地址:

中国浙江省嘉兴南湖区中环南路1882号

Applicant address:

No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang, China

Study leader's address:

No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

314000

研究负责人邮政编码:

Study leader's postcode:

314000

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

The First Hospital of Jiaxing

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

The First Hospital of Jiaxing

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-LP-054

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Hospital of Jiaxing

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-06 00:00:00

伦理委员会联系人:

钱建萍

Contact Name of the ethic committee:

Jianping Qian

伦理委员会联系地址:

中国浙江省嘉兴南湖区中环南路1882号

Contact Address of the ethic committee:

No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 89976378

伦理委员会联系人邮箱:

Contact email of the ethic committee:

jxdyyyll@163.com

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

The First Hospital of Jiaxing

研究实施负责(组长)单位地址:

中国浙江省嘉兴市南湖区中环南路1882号

Primary sponsor's address:

No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

中国浙江省嘉兴市南湖区中环南路1882号

Institution
hospital:

The First Hospital of Jiaxing

Address:

No. 1882 Zhonghuan South Road, Nanhu District, Jiaxing, Zhejiang, China

经费或物资来源:

本研究经费及物资由嘉兴市第一医院耳鼻咽喉科科室经费与科室资源支持;无企业/商业机构资助。

Source(s) of funding:

This study is supported by departmental funds of the Department of Otolaryngology–Head and Neck Surgery, The First Hospital of Jiaxing. No commercial or industry funding is involved.

研究疾病:

慢性扁桃体炎  

Target disease:

Chronic tonsillitis

研究疾病代码:

J35.0

Target disease code:

J35.0

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究taVNS在成人扁桃体手术患者术后镇痛中的安全性与有效性。  

Objectives of Study:

To evaluate the safety and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for postoperative analgesia in adult patients undergoing tonsillectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)拟行择期扁桃体切除术的患者; 2)年龄:18-65岁; 3)麻醉方式与围术期镇痛路径可按研究方案标准化执行:气管插管全麻;基础镇痛方案:术中采用地塞米松5mg静脉推注,术后能定时定量口服对乙酰氨基酚镇痛; 4)术前沟通良好,能理解研究流程并完成疼痛评估(能够使用NRS或研究指定量表); 5)愿意接受耳甲腔贴片刺激并能配合完成规定刺激次数/时长、签署知情同意书的患者; 6)ASA 分级 I–II、一般情况稳定,适合按手术常规流程管理。

Inclusion criteria

1) Patients scheduled for elective tonsillectomy. 2) Age 18–65 years. 3) Anesthesia and perioperative analgesia can be standardized according to the study protocol: general anesthesia with endotracheal intubation; baseline analgesic regimen including a single intraoperative intravenous bolus of dexamethasone 5 mg, and scheduled oral acetaminophen postoperatively. 4) Able to communicate effectively preoperatively, understand the study procedures, and complete pain assessments (able to use the NRS or the study-specified scale). 5) Willing to receive transcutaneous stimulation via a cymba conchae patch electrode and to comply with the prescribed number and duration of stimulation sessions; provides written informed consent. 6) ASA physical status I–II, clinically stable, and suitable for routine perioperative management.

排除标准:

1)既往或目前存在明显心律失常或传导阻滞(Ⅱ/Ⅲ度房室传导阻滞、显著窦性心动过缓等),或有不明原因晕厥史,研究者判断存在心血管安全风险者; 2)体内植入心脏起搏器、植入式除颤器或其他可能受电刺激影响的植入式电子医疗器械者; 3)既往有癫痫/抽搐发作史或近期(如近12个月)有无诱因抽搐发作者; 4)刺激部位存在皮肤破损、感染、湿疹/皮炎或明显过敏反应,不适合贴片刺激者。耳廓畸形或其他原因导致无法规范贴附电极或无法完成规定刺激流程者; 5)术前长期使用阿片类镇痛药或存在药物依赖/滥用史,可能影响术后疼痛评估者; 6)对研究规定的基础镇痛药物存在明确禁忌或严重过敏,导致无法按统一镇痛方案执行者;

Exclusion criteria:

1) History or current evidence of clinically significant arrhythmia or conduction disorder (e.g., second- or third-degree atrioventricular block, marked sinus bradycardia), or a history of unexplained syncope; participants deemed by the investigator to have cardiovascular safety risks. 2) Implanted pacemaker, implantable cardioverter-defibrillator (ICD), or other implanted electronic medical devices that may be affected by electrical stimulation. 3) History of epilepsy/seizures, or any unprovoked seizure within the past 12 months. 4) Skin breakdown, infection, eczema/dermatitis, or significant allergic reaction at the stimulation site, making patch stimulation unsuitable; auricular deformity or other conditions preventing proper electrode placement or completion of the prescribed stimulation protocol. 5)Long-term preoperative opioid use, or a history of substance dependence/abuse that may interfere with postoperative pain assessment. 6)Known contraindication or severe allergy to the protocol-specified baseline analgesics, making it impossible to follow the standardized analgesic regimen.

研究实施时间:

Study execute time:

From 2026-04-01 00:00:00 To 2027-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2027-04-01 00:00:00

干预措施:

Interventions:

组别:

经皮耳迷走神经刺激组

样本量:

40

Group:

Transcutaneous auricular vagus nerve stimulation group

Sample size:

干预措施:

在标准围术期镇痛基础上,给予经皮耳迷走神经刺激(taVNS),刺激部位为耳甲腔(cymba conchae),按研究方案规定的频次与时长实施。

干预措施代码:

taVNS

Intervention:

In addition to standard perioperative analgesia, participants receive transcutaneous auricular vagus nerve stimulation (taVNS) applied to the cymba conchae according to the protocol-defined schedule and duration.

Intervention code:

组别:

假刺激组

样本量:

40

Group:

Sham taVNS group

Sample size:

干预措施:

在标准围术期镇痛基础上,给予假刺激:电极贴附于对照部位/按方案设定为不产生有效神经刺激的参数,刺激流程与实验组一致。

干预措施代码:

Sham

Intervention:

In addition to standard perioperative analgesia, participants receive sham stimulation with the same procedure and schedule as the intervention group but without effective vagal stimulation, according to the protocol.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

嘉兴 

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院 

单位级别:

三甲 

Institution
hospital:

The First Hospital of Jiaxing

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后72 h 吞咽痛NRS评分

指标类型:

主要指标

Outcome:

Swallowing pain NRS score at 72 hours after tonsillectomy

Type:

Primary indicator

测量时间点:

术后72 h

测量方法:

0–10分数字评分法(NRS),0=无痛,10=最剧烈疼痛;吞咽状态评估

Measure time point of outcome:

Postoperative 72 h

Measure method:

0–10 Numerical Rating Scale (NRS), assessed during swallowing (0=no pain, 10=worst imaginable pain)

指标中文名:

术后72 h 静息痛NRS评分

指标类型:

次要指标

Outcome:

Resting pain NRS score at 72 hours after tonsillectomy

Type:

Secondary indicator

测量时间点:

术后72 h

测量方法:

0–10分数字评分法(NRS),0=无痛,10=最剧烈疼痛;静息状态评估

Measure time point of outcome:

Postoperative 72 h

Measure method:

0–10 Numerical Rating Scale (NRS), 0=no pain and 10=worst imaginable pain; assessed at rest

指标中文名:

术后6/24/48/72 h 吞咽痛NRS评分

指标类型:

次要指标

Outcome:

Swallowing pain NRS scores at 6, 24, 48 and 72 hours after tonsillectomy

Type:

Secondary indicator

测量时间点:

术后6 h、24 h、48 h、72 h

测量方法:

0–10分NRS;嘱患者吞咽一次后即刻评估吞咽痛

Measure time point of outcome:

Postoperative 6/24/48/72 h

Measure method:

0–10 NRS assessed immediately after a swallow at each time point

指标中文名:

术后6/24/48/72 h 静息痛NRS评分

指标类型:

次要指标

Outcome:

Resting pain NRS scores at 6, 24, 48 and 72 hours after tonsillectomy

Type:

Secondary indicator

测量时间点:

术后6 h、24 h、48 h、72 h

测量方法:

0–10分NRS;静息状态评估

Measure time point of outcome:

Postoperative 6/24/48/72 h

Measure method:

0–10 NRS assessed at rest at each time point

指标中文名:

术后首次补救镇痛时间

指标类型:

次要指标

Outcome:

Time to first rescue analgesia after tonsillectomy

Type:

Secondary indicator

测量时间点:

术后0–72 h

测量方法:

记录从手术结束至首次使用补救镇痛药的时间(小时)

Measure time point of outcome:

Postoperative 0–72 h

Measure method:

Time (hours) from end of surgery to the first administration of rescue analgesics

指标中文名:

术后不良事件

指标类型:

次要指标

Outcome:

Adverse events

Type:

Secondary indicator

测量时间点:

术后10天内

测量方法:

由研究人员在术后0–10天随访中记录所有不良事件(类型、发生时间、严重程度及处理)。

Measure time point of outcome:

Postoperative day 0–10

Measure method:

AEs/SAEs will be collected by study staff through in-hospital assessment and post-discharge follow-up within POD0–10, and recorded with event type, onset time, severity, and management/outcome; relatedness to the intervention will be assessed per protocol.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

N/A

人体标本去向

其它  

说明

本研究不采集任何人体生物标本(如血液、唾液、组织等),仅收集临床资料与疼痛评估数据。

Fate of sample:

0thers  

Note:

No human biological specimens (e.g., blood, saliva, tissue) will be collected in this study; only clinical data and pain assessments will be recorded.

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机生成的随机数字表,将受试者按1:1比例随机分配至taVNS组(干预组)与假刺激组(对照组)。随机数列由方案设计者密封保存。分配信息置于不透明密封信封中,直至准备启动第一次干预前始终保持分配隐藏。

Randomization Procedure (please state who generates the random number sequence and by what method):

A computer-generated random number list will be used to allocate participants in a 1:1 ratio to the taVNS group (intervention) or the sham stimulation group (control). The randomization sequence will be kept sealed by the protocol designer. Allocation details will be placed in sequentially numbered, opaque sealed envelopes and will remain concealed until immediately before the first intervention session.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

受试者和结局评估人员(病房随访/电话随访人员)对分组未知。taVNS组与假刺激组在电极贴附方式、操作流程、干预时长及随访安排上保持一致,由专人根据分组实施刺激。统计分析人员在数据库锁定前对分组信息保持盲态。

Blinding:

Participants and outcome assessors (in-hospital and post-discharge follow-up staff) will be blinded to group allocation. The taVNS and sham groups will receive identical electrode placement procedures, session duration and follow-up schedules; stimulation will be delivered by designated personnel according to allocation. The statistician will remain blinded to group assignment until database lock.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用统一病例报告表进行数据采集,包括基线资料、手术与麻醉信息、干预执行情况、疼痛评分、补救镇痛用药、不良事件及随访记录等。数据由研究人员双人核对后录入电子数据库Excel,定期进行逻辑核查与缺失值核查;所有数据采用编号化管理,纸质资料与电子数据分别由专人保管,电子数据设置访问权限并定期备份。研究结束后进行数据库锁定。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will be collected using standardized case report forms (CRFs), including baseline characteristics, perioperative information, intervention delivery, pain scores, rescue analgesic use, adverse events and follow-up records. Data will be checked by two study staff and entered into an electronic database (Excel). Regular data cleaning will be performed, including range checks, logic checks and missing data queries. All participants will be assigned unique study IDs; paper records and electronic files will be stored securely with restricted access, and electronic data will be backed up regularly. The database will be locked at the end of the study and no changes will be made without authorization.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-03-25 08:52:45